Snowflake Score | |
---|---|
Valuation | 0/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
TNG Stock Overview
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases.
Transgene Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | €2.35 |
52 Week High | €3.15 |
52 Week Low | €1.60 |
Beta | 0.87 |
1 Month Change | -1.05% |
3 Month Change | 8.55% |
1 Year Change | -13.92% |
3 Year Change | -20.34% |
5 Year Change | -29.43% |
Change since IPO | -94.78% |
Recent News & Updates
Does Transgene (EPA:TNG) Have A Healthy Balance Sheet?
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...
Shareholder Returns
TNG | FR Biotechs | FR Market | |
---|---|---|---|
7D | -0.2% | 3.6% | -1.5% |
1Y | -13.9% | -39.9% | -18.8% |
Return vs Industry: TNG exceeded the French Biotechs industry which returned -39% over the past year.
Return vs Market: TNG underperformed the French Market which returned -5.4% over the past year.
Price Volatility
TNG volatility | |
---|---|
TNG Average Weekly Movement | 7.6% |
Biotechs Industry Average Movement | 8.7% |
Market Average Movement | 6.0% |
10% most volatile stocks in FR Market | 10.2% |
10% least volatile stocks in FR Market | 3.5% |
Stable Share Price: TNG is not significantly more volatile than the rest of French stocks over the past 3 months, typically moving +/- 8% a week.
Volatility Over Time: TNG's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1979 | 143 | Hedi Brahim | https://www.transgene.fr |
Transgene SA, a biotechnology company, focuses on designing and developing therapeutic vaccines and oncolytic viruses for the treatment of cancer and infectious diseases. It is involved in developing TG4050, a therapeutic vaccine that is in phase I clinical trial for the treatment of ovarian cancer, and human papilloma virus (HPV)-negative head and neck cancers; TG4001, a therapeutic vaccine, which is in phase II clinical trial for the treatment of HPV-positive cancers; TG6002, an oncolytic virus that is in phase I/IIa clinical trial for the treatment of various solid tumors, such as gastrointestinal adenocarcinoma comprising stomach, pancreas, and colon; and BT-001, an oncolytic virus, which is in phase I/II clinical trial for the treatment of solid tumors. The company also develops TG1050, a therapeutic vaccine for the treatment of chronic hepatitis B; and Pexa-Vec, an oncolytic virus for the treatment of solid tumors.
Transgene Fundamentals Summary
TNG fundamental statistics | |
---|---|
Market Cap | €233.52m |
Earnings (TTM) | -€19.54m |
Revenue (TTM) | €17.01m |
13.7x
P/S Ratio-12.0x
P/E RatioIs TNG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
TNG income statement (TTM) | |
---|---|
Revenue | €17.01m |
Cost of Revenue | €32.88m |
Gross Profit | -€15.87m |
Other Expenses | €3.67m |
Earnings | -€19.54m |
Last Reported Earnings
Dec 31, 2021
Next Earnings Date
Sep 07, 2022
Earnings per share (EPS) | -0.20 |
Gross Margin | -93.27% |
Net Profit Margin | -114.82% |
Debt/Equity Ratio | 19.2% |
How did TNG perform over the long term?
See historical performance and comparisonValuation
Is Transgene undervalued compared to its fair value and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
PE vs Industry
PE vs Market
PEG Ratio
PB vs Industry
3.47x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate TNG's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate TNG's fair value for valuation analysis.
Price To Earnings Ratio
PE vs Industry: TNG is unprofitable, so we can't compare its PE Ratio to the European Biotechs industry average.
PE vs Market: TNG is unprofitable, so we can't compare its PE Ratio to the French market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate TNG's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: TNG is overvalued based on its PB Ratio (3.5x) compared to the FR Biotechs industry average (2.6x).
Future Growth
How is Transgene forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?
Future Growth Score
0/6Future Growth Score 0/6
Earnings vs Savings Rate
Earnings vs Market
High Growth Earnings
Revenue vs Market
High Growth Revenue
Future ROE
-27.3%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: TNG is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: TNG is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: TNG is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: TNG's revenue is expected to decline over the next 3 years (-14.1% per year).
High Growth Revenue: TNG's revenue is forecast to decline over the next 3 years (-14.1% per year).
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: TNG is forecast to be unprofitable in 3 years.
Past Performance
How has Transgene performed over the past 5 years?
Past Performance Score
0/6Past Performance Score 0/6
Quality Earnings
Growing Profit Margin
Earnings Trend
Accelerating Growth
Earnings vs Industry
High ROE
10.6%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: TNG is currently unprofitable.
Growing Profit Margin: TNG is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: TNG is unprofitable, but has reduced losses over the past 5 years at a rate of 10.6% per year.
Accelerating Growth: Unable to compare TNG's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: TNG is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-6.2%).
Return on Equity
High ROE: TNG has a negative Return on Equity (-29.07%), as it is currently unprofitable.
Financial Health
How is Transgene's financial position?
Financial Health Score
6/6Financial Health Score 6/6
Short Term Liabilities
Long Term Liabilities
Debt Level
Reducing Debt
Stable Cash Runway
Forecast Cash Runway
Financial Position Analysis
Short Term Liabilities: TNG's short term assets (€62.2M) exceed its short term liabilities (€14.6M).
Long Term Liabilities: TNG's short term assets (€62.2M) exceed its long term liabilities (€20.0M).
Debt to Equity History and Analysis
Debt Level: TNG has more cash than its total debt.
Reducing Debt: TNG's debt to equity ratio has reduced from 117.8% to 19.2% over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: TNG has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: TNG has sufficient cash runway for 1.3 years if free cash flow continues to grow at historical rates of 6.5% each year.
Dividend
What is Transgene current dividend yield, its reliability and sustainability?
Dividend Score
0/6Dividend Score 0/6
Notable Dividend
High Dividend
Stable Dividend
Growing Dividend
Earnings Coverage
Future Dividend Coverage
Dividend Yield vs Market
Notable Dividend: Unable to evaluate TNG's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate TNG's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if TNG's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if TNG's dividend payments have been increasing.
Earnings Payout to Shareholders
Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Cash Payout to Shareholders
Cash Flow Coverage: Unable to calculate sustainability of dividends as TNG has not reported any payouts.
Discover strong dividend paying companies
Management
How experienced are the management team and are they aligned to shareholders interests?
6.2yrs
Average management tenure
CEO
Hedi Brahim (40 yo)
1.33yrs
Tenure
€2,208,000
Compensation
Mr. Hedi Ben Brahim serves as the Chairman of the Board and Chief Executive Officer at Transgene SA since January 01, 2021. He serves as served as Director at ElsaLys Biotech SA until 2019. He has been Dir...
CEO Compensation Analysis
Compensation vs Market: Hedi's total compensation ($USD2.36M) is above average for companies of similar size in the French market ($USD385.78K).
Compensation vs Earnings: Insufficient data to compare Hedi's compensation with company performance.
Leadership Team
Experienced Management: TNG's management team is seasoned and experienced (6.2 years average tenure).
Board Members
Experienced Board: TNG's board of directors are considered experienced (4.9 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 18.8%.
Top Shareholders
Company Information
Transgene SA's employee growth, exchange listings and data sources
Key Information
- Name: Transgene SA
- Ticker: TNG
- Exchange: ENXTPA
- Founded: 1979
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Implied Market Cap: €233.519m
- Shares outstanding: 99.37m
- Website: https://www.transgene.fr
Number of Employees
Location
- Transgene SA
- 400, Boulevard Gonthier d’Andernach
- Parc d’Innovation – CS80166
- Illkirch-Graffenstaden
- Alsace
- 67405
- France
Listings
Company Analysis and Financial Data Status
Data | Last Updated (UTC time) |
---|---|
Company Analysis | 2022/05/23 00:00 |
End of Day Share Price | 2022/05/23 00:00 |
Earnings | 2021/12/31 |
Annual Earnings | 2021/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.